Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 3/2014

01.06.2014 | Research Article

Clinical pharmacist’s role in implementing a smoking cessation intervention in a Swiss regional hospital: an exploratory study

verfasst von: Maria Dobrinas, Anne-Laure Blanc, François Rouiller, Grégoire Christen, Marcos Coronado, Damien Tagan, Christian Schäli

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Background Smoking cessation represents one of the best means of preventing smoking-related complications. In recent years, a majority of hospitals have implemented smoke-free policies, making support for smoker patients a necessary and indispensable task. The clinical pharmacist is well-positioned to provide this kind of support, given a good understanding of the medical condition and pharmacotherapy of hospitalized patients and the possibility to acquire specific smoking cessation training. Objectives This study aimed to evaluate the impact of a smoking cessation intervention for hospitalized patients by a clinical pharmacist previously trained for smoking cessation counselling. Setting Internal medicine department of a Swiss regional hospital. Method Smoker patients hospitalized in this department were included in the study from mid-September 2012 to mid-January 2013, according to the inclusion criteria. Moderate-intensity smoking cessation interventions based on smoking counselling and motivational interviewing techniques were used, and a follow-up telephone call at least 1 month after discharge was made. Patients’ pharmacotherapy was analysed with regards to interactions with tobacco smoke. Main outcome measures Motivational stage, abstinence at follow-up, change of readiness to quit between hospital visit and follow-up, patients’ evaluation of the programme, pharmacotherapy interventions. Results One hundred smoker patients were screened, of whom 41 received the intervention and 40 received a follow-up contact. At least 1 month after discharge, the readiness to quit of 53 % of patients improved and 33 % of patients declared themselves abstinent. Even though 35 % of patients declared having mild to moderate withdrawal symptoms in hospital, only 15 % were interested in receiving nicotine replacement therapy. Study participants evaluated the intervention positively. Conclusion A moderate-intensity smoking cessation intervention in hospitalized patients was associated with a higher quit rate than in control groups from other studies, and their readiness to quit generally improved at least 1 month after hospital discharge. A clinical pharmacist trained for smoking cessation counselling can play a key role in providing such interventions, including the assessment of pharmacotherapy interactions with tobacco smoke.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat The health benefits of smoking cessation. U.S. Department of Health and Human Services. Public Health Service. Centers for Disease Control. Center for Chronic Disease Prevention and Health Promotion. Office on Smoking and Health. DHHS Publication No. (CDC) YO-K-116. 1990. http://www.surgeongeneral.gov/library/reports. Accessed 7 Oct 2013. The health benefits of smoking cessation. U.S. Department of Health and Human Services. Public Health Service. Centers for Disease Control. Center for Chronic Disease Prevention and Health Promotion. Office on Smoking and Health. DHHS Publication No. (CDC) YO-K-116. 1990. http://​www.​surgeongeneral.​gov/​library/​reports. Accessed 7 Oct 2013.
3.
Zurück zum Zitat Rigotti NA, Munafò MR, Stead LF. Smoking cessation interventions for hospitalized smokers: a systematic review. Arch Intern Med. 2008;168(18):1950–60.PubMedCrossRef Rigotti NA, Munafò MR, Stead LF. Smoking cessation interventions for hospitalized smokers: a systematic review. Arch Intern Med. 2008;168(18):1950–60.PubMedCrossRef
4.
Zurück zum Zitat Rigotti NA, Clair C, Munafò MR, Stead LF. Interventions for smoking cessation in hospitalized patients. Cochrane Database Syst Rev. 2012; Issue 5. Art. No: CD001837. Rigotti NA, Clair C, Munafò MR, Stead LF. Interventions for smoking cessation in hospitalized patients. Cochrane Database Syst Rev. 2012; Issue 5. Art. No: CD001837.
5.
Zurück zum Zitat Liu SK, Prior E, Warren C, Brown T, Snide J, Butterly JR. Improving the quality of care for the hospitalized tobacco user—one institution’s transformational journey. J Canerc Educ. 2010;25:297–301.CrossRef Liu SK, Prior E, Warren C, Brown T, Snide J, Butterly JR. Improving the quality of care for the hospitalized tobacco user—one institution’s transformational journey. J Canerc Educ. 2010;25:297–301.CrossRef
6.
Zurück zum Zitat Schroeder SA. Smoking among hospitalized patients. Another opportunity to improve patients’ health. Arch Intern Med. 2012;172(21):1675–6.PubMedCrossRef Schroeder SA. Smoking among hospitalized patients. Another opportunity to improve patients’ health. Arch Intern Med. 2012;172(21):1675–6.PubMedCrossRef
7.
Zurück zum Zitat Reid RD, Mullen K-A, D’Angelo MES, Aitken DA, Papadakis S. Smoking cessation for hospitalized smokers: an evaluation of the “Ottawa Model”. Nicot Tob Res. 2010;12(1):11–8. Reid RD, Mullen K-A, D’Angelo MES, Aitken DA, Papadakis S. Smoking cessation for hospitalized smokers: an evaluation of the “Ottawa Model”. Nicot Tob Res. 2010;12(1):11–8.
8.
Zurück zum Zitat Bize R, Stoianov R, Ruffieux C, Ghali W, Paccaud F, Cornuz J. Effectiveness of a low-intensity smoking cessation intervention for hospitalized patients. Eur J Cancer Prev. 2006;15(5):464–70.PubMedCrossRef Bize R, Stoianov R, Ruffieux C, Ghali W, Paccaud F, Cornuz J. Effectiveness of a low-intensity smoking cessation intervention for hospitalized patients. Eur J Cancer Prev. 2006;15(5):464–70.PubMedCrossRef
9.
Zurück zum Zitat Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther. 2008;83(4):531–41.PubMedCrossRef Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther. 2008;83(4):531–41.PubMedCrossRef
10.
Zurück zum Zitat Kroon LA. Drug interactions with smoking. Am Soc Health Syst Pharm. 2007;64(18):1917–21.CrossRef Kroon LA. Drug interactions with smoking. Am Soc Health Syst Pharm. 2007;64(18):1917–21.CrossRef
12.
Zurück zum Zitat Dent LA, Harris KJ, Noonan CW. Randomized trial assessing the effectiveness of a pharmacist-delivered program for smoking cessation. Ann Pharmacother. 2009;43:194–201.PubMed Dent LA, Harris KJ, Noonan CW. Randomized trial assessing the effectiveness of a pharmacist-delivered program for smoking cessation. Ann Pharmacother. 2009;43:194–201.PubMed
13.
Zurück zum Zitat Fiore MC. Treating tobacco use and dependence: 2008 update U.S. Public Health Service. Clinical practice guideline executive summary. Respir Care. 2008;53(9):1217–22. Fiore MC. Treating tobacco use and dependence: 2008 update U.S. Public Health Service. Clinical practice guideline executive summary. Respir Care. 2008;53(9):1217–22.
14.
Zurück zum Zitat Dobrinas M, Cornuz J, Oneda B, Serra MK, Puhl M, Eap CB. Impact of smoking, smoking cessation and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther. 2011;90:117–25.PubMedCrossRef Dobrinas M, Cornuz J, Oneda B, Serra MK, Puhl M, Eap CB. Impact of smoking, smoking cessation and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther. 2011;90:117–25.PubMedCrossRef
15.
Zurück zum Zitat Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström test for nicotine dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119–27.PubMedCrossRef Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström test for nicotine dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119–27.PubMedCrossRef
16.
Zurück zum Zitat West R, Hajek P. Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal. Psychopharmacol (Berl). 2004;177(1–2):195–9.CrossRef West R, Hajek P. Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal. Psychopharmacol (Berl). 2004;177(1–2):195–9.CrossRef
17.
Zurück zum Zitat Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983;51:390–5.PubMedCrossRef Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983;51:390–5.PubMedCrossRef
18.
Zurück zum Zitat Stop-tabac.ch [Internet]. University of Geneva, Institute of Social and Preventive Medicine [Université de Genève, Institut de médecine sociale et préventive]. http://www.stop-tabac.ch. Accessed 25 Sept 2013. Stop-tabac.ch [Internet]. University of Geneva, Institute of Social and Preventive Medicine [Université de Genève, Institut de médecine sociale et préventive]. http://​www.​stop-tabac.​ch. Accessed 25 Sept 2013.
19.
Zurück zum Zitat Skogh E, Bengtsson F, Nordin C. Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. Ther Drug Monit. 1999;21:580–2.PubMedCrossRef Skogh E, Bengtsson F, Nordin C. Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. Ther Drug Monit. 1999;21:580–2.PubMedCrossRef
20.
Zurück zum Zitat Zullino DF, Delessert D, Eap CB, Preisig M, Baumann P. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol. 2002;17:141–3.PubMedCrossRef Zullino DF, Delessert D, Eap CB, Preisig M, Baumann P. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol. 2002;17:141–3.PubMedCrossRef
21.
Zurück zum Zitat Wahawisan J, Kolluru S, Nguyen T, Molina C, Speake J. Methadone toxicity due to smoking cessation—a case report on the drug–drug interaction involving cytochrome P450 isoenzyme 1A2. Ann Pharmacother. 2011;45(6):e34.PubMedCrossRef Wahawisan J, Kolluru S, Nguyen T, Molina C, Speake J. Methadone toxicity due to smoking cessation—a case report on the drug–drug interaction involving cytochrome P450 isoenzyme 1A2. Ann Pharmacother. 2011;45(6):e34.PubMedCrossRef
22.
Zurück zum Zitat Dobrinas M, Cornuz J, Serra MK, Puhl M, Eap CB. Genetic aspects of smoking and impact on clinical care. Rev Med Suisse. 2009;5(210):1463–7.PubMed Dobrinas M, Cornuz J, Serra MK, Puhl M, Eap CB. Genetic aspects of smoking and impact on clinical care. Rev Med Suisse. 2009;5(210):1463–7.PubMed
23.
Zurück zum Zitat Fjalldal SB, Janson C, Benediktsdottir B, Gudmundsson G, Burney P, et al. Smoking, stages of change and decisional balance in Iceland and Sweden. Clin Respir J. 2011;5(2):76–83.PubMedCrossRef Fjalldal SB, Janson C, Benediktsdottir B, Gudmundsson G, Burney P, et al. Smoking, stages of change and decisional balance in Iceland and Sweden. Clin Respir J. 2011;5(2):76–83.PubMedCrossRef
24.
Zurück zum Zitat Keller R, Radtke T, Krebs H, Hornung R. Tobacco consumption in the Swiss population between 2001 and 2010. Tobacco monitoring – Swiss Tobacco Survey. Summary of the 2011 research report [La consommation de tabac dans la population suisse de 2001 à 2010. Monitorage sur le tabac – Enquête suisse sur le tabagisme. Résumé du rapport de recherche 2011]. http://www.tabakmonitoring.ch/ResultatsConsommation.html. Accessed 25 Sept 2013. Keller R, Radtke T, Krebs H, Hornung R. Tobacco consumption in the Swiss population between 2001 and 2010. Tobacco monitoring – Swiss Tobacco Survey. Summary of the 2011 research report [La consommation de tabac dans la population suisse de 2001 à 2010. Monitorage sur le tabac – Enquête suisse sur le tabagisme. Résumé du rapport de recherche 2011]. http://​www.​tabakmonitoring.​ch/​ResultatsConsomm​ation.​html. Accessed 25 Sept 2013.
25.
Zurück zum Zitat Buckland A, Connolly MJ. Age-related differences in smoking cessation advice and support given to patients hospitalised with smoking-related illness. Age Ageing. 2005;34(6):639–42.PubMedCrossRef Buckland A, Connolly MJ. Age-related differences in smoking cessation advice and support given to patients hospitalised with smoking-related illness. Age Ageing. 2005;34(6):639–42.PubMedCrossRef
26.
Zurück zum Zitat Fiore MC, Baker TB. Should clinicians encourage smoking cessation for every patient who smokes? JAMA. 2013;309(10):1032–3.PubMedCrossRef Fiore MC, Baker TB. Should clinicians encourage smoking cessation for every patient who smokes? JAMA. 2013;309(10):1032–3.PubMedCrossRef
27.
Zurück zum Zitat Dent LA, Harris KJ, Noonan KV. Tobacco interventions delivered by pharmacists: a summary and systematic review. Pharmacotherapy. 2007;27(7):1040–51.PubMedCrossRef Dent LA, Harris KJ, Noonan KV. Tobacco interventions delivered by pharmacists: a summary and systematic review. Pharmacotherapy. 2007;27(7):1040–51.PubMedCrossRef
28.
Zurück zum Zitat Warner TD, Clark MP, Mitchell JA. Smoking, atherothrombosis and clopidogrel. Heart. 2012;98(13):963–4.PubMedCrossRef Warner TD, Clark MP, Mitchell JA. Smoking, atherothrombosis and clopidogrel. Heart. 2012;98(13):963–4.PubMedCrossRef
Metadaten
Titel
Clinical pharmacist’s role in implementing a smoking cessation intervention in a Swiss regional hospital: an exploratory study
verfasst von
Maria Dobrinas
Anne-Laure Blanc
François Rouiller
Grégoire Christen
Marcos Coronado
Damien Tagan
Christian Schäli
Publikationsdatum
01.06.2014
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 3/2014
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-014-9927-8

Weitere Artikel der Ausgabe 3/2014

International Journal of Clinical Pharmacy 3/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.